OPKO Health Inc
OPK1.240USD
+0.010+0.81%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
953.19MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über OPKO Health Inc Unternehmen
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
OPKO Health Inc Informationen
BörsenkürzelOPK
Name des UnternehmensOPKO Health Inc
IPO-datumNov 02, 1995
CEOCruz (Tony F)
Anzahl der mitarbeiter2997
WertpapierartOrdinary Share
GeschäftsjahresendeNov 02
Addresse- -
Stadt- -
BörseNASDAQ OMX - NASDAQ BASIC
Land- -
Postleitzahl- -
Telefon- -
Website- -
BörsenkürzelOPK
IPO-datumNov 02, 1995
CEOCruz (Tony F)
Führungskräfte von OPKO Health Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-437500.00%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-500000.00%
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Independent Director
Independent Director
66.49K
--
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
--
--
Dr. Phillip Frost ,M.D.
Dr. Phillip Frost ,M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
--
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
--
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Dr. Charles W. Bishop, Ph.D.
Dr. Charles W. Bishop, Ph.D.
Chief Executive Officer of OPKO Renal
Chief Executive Officer of OPKO Renal
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-437500.00%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-500000.00%
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Independent Director
Independent Director
66.49K
--
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
--
--
Dr. Phillip Frost ,M.D.
Dr. Phillip Frost ,M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Health Insurers
53.91M
56.61%
Client Payers
23.51M
24.68%
Government Payers
15.60M
16.38%
Patients
2.22M
2.33%
Nach RegionUSD
Name
Umsatz
Anteil
United States
110.92M
73.13%
Chile
14.36M
15.08%
Ireland
12.08M
12.68%
Mexico
6.74M
7.07%
Spain
6.34M
6.65%
Andere
-55.19M
-14.62%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Health Insurers
53.91M
56.61%
Client Payers
23.51M
24.68%
Government Payers
15.60M
16.38%
Patients
2.22M
2.33%
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Frost Gamma Investments Trust
28.98%
Rubric Capital Management LP
6.23%
Holbrook (Bruce C)
5.26%
Hsiao (Jane H)
4.32%
The Vanguard Group, Inc.
4.21%
Andere
51.01%
Aktionäre
Aktionäre
Anteil
Frost Gamma Investments Trust
28.98%
Rubric Capital Management LP
6.23%
Holbrook (Bruce C)
5.26%
Hsiao (Jane H)
4.32%
The Vanguard Group, Inc.
4.21%
Andere
51.01%
Aktionärstypen
Aktionäre
Anteil
Corporation
38.14%
Investment Advisor
11.81%
Individual Investor
10.57%
Hedge Fund
7.45%
Investment Advisor/Hedge Fund
5.35%
Research Firm
0.48%
Bank and Trust
0.21%
Pension Fund
0.14%
Family Office
0.05%
Andere
25.82%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
453
195.32M
25.44%
-57.10M
2025Q3
457
208.31M
27.13%
-63.18M
2025Q2
472
618.23M
77.88%
-578.48K
2025Q1
498
645.32M
88.41%
+25.74M
2024Q4
501
573.04M
84.80%
-7.63M
2024Q3
497
562.18M
81.01%
-12.00M
2024Q2
501
553.77M
79.70%
+8.59M
2024Q1
492
531.83M
76.52%
-21.84M
2023Q4
493
533.01M
69.65%
+31.42M
2023Q3
496
529.79M
69.24%
+23.70M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Frost Gamma Investments Trust
222.46M
28.98%
+2.15M
+0.98%
Nov 21, 2025
Rubric Capital Management LP
47.79M
6.23%
--
--
Sep 30, 2025
Holbrook (Bruce C)
40.38M
5.26%
--
--
Feb 24, 2025
Hsiao (Jane H)
33.13M
4.32%
--
--
Apr 02, 2025
The Vanguard Group, Inc.
37.45M
4.88%
-702.82K
-1.84%
Sep 30, 2025
Frost Group, L.L.C.
30.13M
3.92%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
29.68M
3.87%
+1.46M
+5.19%
Sep 30, 2025
GJN 2021 Trust
19.91M
2.59%
--
--
Feb 24, 2025
EGN 2021 Trust
19.91M
2.59%
--
--
Feb 24, 2025
Geode Capital Management, L.L.C.
10.99M
1.43%
+568.87K
+5.46%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
0.53%
State Street SPDR S&P Health Care Services ETF
0.46%
VanEck Israel ETF
0.14%
Humankind US Stock ETF
0.1%
iShares U.S. Healthcare Providers ETF
0.1%
Goldman Sachs Innovate Equity ETF
0.06%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.04%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil0.53%
State Street SPDR S&P Health Care Services ETF
Anteil0.46%
VanEck Israel ETF
Anteil0.14%
Humankind US Stock ETF
Anteil0.1%
iShares U.S. Healthcare Providers ETF
Anteil0.1%
Goldman Sachs Innovate Equity ETF
Anteil0.06%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Anteil0.05%
iShares Russell 2000 Value ETF
Anteil0.04%
iShares Biotechnology ETF
Anteil0.04%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.04%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
